Vol 2 Chapter 1567: Dazzling clinical trial results

Therefore, these patients did not have much resistance to the experiment of this new drug. After explaining some things, they all accepted the new drug experiment project immediately. Immediately, we began to take medications for these patients according to their conditions, and conducted round-the-clock physical examinations. "

While Wu Hao was speaking, a series of related data and information began to float above his head.

"Look here, everyone. This is the test result after one day of taking the medicine. This is the test result after a week. The following are the test results for one month, two months, and three months. Wu Hao introduced to everyone.

The data is now, one day after taking the medicine, more than 85 percent of the patients' stomach H. pylori carbon 13 breath test value dropped significantly.

After taking the medicine for two days, 98% of the patients' stomach H. pylori carbon 13 breath test value dropped significantly. This is the test result three days after taking the medicine. Among them, 100% of the patients' stomach H. pylori carbon 13 breath test value dropped significantly, and even some patients' stomach H. pylori carbon 13 breath test value has reached normal Numerical value. "

"We immediately performed gastric examinations and gastric juice and tissue biopsies on the relevant patients, and there were no signs of Helicobacter pylori."

"This is a comprehensive test result after one week of treatment. We can see that 97% of the patients' gastric Helicobacter pylori carbon 13 breath test value has reached the normal value, and neither gastric juice nor tissue biopsy has been found. Helicobacter pylori in the stomach. And some patients' stomachs have been cured very obviously, and the weight of many patients with conservative stomach troubles has also increased."

"This is the result of our re-examination one month later. Ninety-nine percent of the patients have fully recovered, the Helicobacter pylori in the stomach has been cleared, and the stomach disease has been cured. Only 1% of the patients have the stomach Helicobacter pylori has been significantly suppressed, but the stomach has not recovered. Two of the patients have the possibility of repeated infection."

It can be said that this new drug has a very significant and ideal therapeutic effect on H. pylori in the stomach. Compared with the current most popular triple and quadruple therapy, the effect is faster and the entire treatment course is shorter. Recovery is also faster.

In addition, we also conduct comprehensive monitoring of the patient's body, including the metabolism of our drug in the human body. In particular, many people worry that this kind of super phage will mutate and stay in the human body. We have carried out strict monitoring.

Data show that the super phage in the drug will quickly find and swallow Helicobacter pylori in the stomach after entering the stomach of the patient. The more Helicobacter pylori in the stomach, the more phagocytic division of this super phage. With the rapid decrease in the number of Helicobacter pylori in the stomach, these active super phages will begin to lose their activity due to the reduction in food and eventually die.

They will be gradually excreted from the body with the metabolism of the intestines and stomach. After stopping the drug, the entire metabolism time will be around forty-eight hours, and it will be able to metabolize cleanly.

We monitored all patients in the first phase of the clinical trial. All patients had super phage after taking the drug. Eighty percent of the patients were completely metabolized within 48 hours after stopping the drug. A small number of patients suffer from gastrointestinal metabolism disorders, so the metabolism time is relatively slow, but they also have a clean metabolism within a week.

In all patients, no super phage staying in the body was detected, and no super phage mutation was found. There are also no case reports of super phage allergies and side effects. Other patients with underlying diseases did not aggravate their illnesses after taking super phage. "

Speaking of this, Wu Hao smiled at everyone in the audience and said: "Here, one of our clinical trials has ended perfectly. We have achieved very satisfactory results in this clinical trial. These data reports further prove that our new The efficacy and safety of the drug.

Immediately we applied to start the second phase of clinical trials. This time we expanded the scale of patients, whether it was cooperating with many domestic hospitals, and we also conducted clinical trials in the hospital systems of some overseas countries.

This time, we selected a total of 23,000 patients for Phase II clinical trials, including 20,000 domestic patients and 3,000 overseas patients.

And this time, we have extended the scope of testing to all patients who are disturbed by Helicobacter pylori in the stomach, instead of focusing only on critically ill patients as in the first phase.

Therefore, in the second phase clinical trial, we obtained a very rich report of massive data information.

The massive data and information we obtained from the entire Phase II clinical trial show that our new drug has a cure rate of 98.7% for Helicobacter pylori infection in the stomach. All patients who participated in the Phase II clinical trial had any rejection allergic reactions during the medication period, and there were no reports of any side effects.

All patients were completely metabolized within 48 hours to one week after stopping the drug, and did not receive any reports of super phage infection in the stomach.

It can be said that the entire Phase II clinical trial has further confirmed the efficacy and safety of our new drug. "

"In order to ensure the authenticity of the entire experimental data, all experimental data collection results are entrusted to domestic and international professional medical data collection institutions. They are specifically responsible for them. We will not interfere in the whole process. And the whole process There are also relevant departments and expert groups to supervise, and there are no violations or cheating in the whole process."

While Wu Hao was speaking, relevant reports and documents were simultaneously displayed above his head to prove to everyone the authenticity of what he said.

After introducing these, Wu Hao took a sigh of relief, and then continued: "During the entire testing process, we strictly followed the international clinical trial standards for new drugs.

In accordance with relevant regulations, a comprehensive monitoring of fungal infections that this biopharmaceutical may cause has been carried out. We collected all patients' excretion and feces and compared them with laboratory tests. The super phage in its excrement has lost its activity and does not have the ability to infect. This result also confirms the safety and environmental protection of this new drug. "

At present, we have stepped up efforts to sort out the data of Phase II clinical trials, and began to step up application and preparations for larger-scale Phase III clinical trials. It is expected that the entire experimental cycle will be about six months. We will conduct clinical trials in more than 500 hospitals across the country, and this time will cover 100,000 patients.

If all the results of the experiment go well, we will immediately begin to apply for the listing of this new drug. According to the normal process, it is expected that this new drug will be launched next year.